Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR | Synapse

March 21, 2023Open Access

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

tumors in vivo. CAT/9A8 CART is being tested in a phase I clinical study (NCT02443831).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Kokalaki et al. (Tue,) studied this question.

synapsesocial.com/papers/6a08869b113ba5b476de3ee6 https://doi.org/https://doi.org/10.1016/j.ymthe.2023.03.020

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia2011 · 2,415 citations
2cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.1991 · 152 citations
3TCR-Like Human Antibodies Expressed on Human CTLs Mediate Antibody Affinity-Dependent Cytolytic Activity2002 · 78 citations
4CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy2017 · 1,357 citations
5Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells2021 · 204 citations